Unknown

Dataset Information

0

Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag.

ABSTRACT: HIV-associated thrombocytopenia is a disease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag - a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a temporizing measure.

SUBMITTER: Vijayakrishnan R 

PROVIDER: S-EPMC3981206 | biostudies-other | 2011 Mar

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag.

Vijayakrishnan Rajakrishnan R   Dani Sourbha S   Ramasubramanian Aparna A   Nair Rekha R   Samaha Tony M TM  

Clinics and practice 20110329 1

HIV-associated thrombocytopenia is a disease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag - a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be us  ...[more]